EIF4A2

Eukaryotic initiation factor 4A-II · Q14240 · EIF4A2 on Sugi Atlas →

88 patent compounds predicted against EIF4A2, 64 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Hippuristanol Hippuristanol (SCHEMBL1374807) 1.00 1/20
Epihippuristanol Epihippuristanol (SCHEMBL21358104) 1.00 1/20
Epihippurin 1 Epihippurin 1 (SCHEMBL30088348) 0.68 1/20
SCHEMBL11438646 SCHEMBL11438646 0.56 1/20
SCHEMBL17790599 SCHEMBL17790599 0.56 1/20
SCHEMBL17790601 SCHEMBL17790601 0.56 1/20
SCHEMBL17790603 SCHEMBL17790603 0.56 1/20
SCHEMBL17790604 SCHEMBL17790604 0.56 1/20
SCHEMBL17790606 SCHEMBL17790606 0.56 1/20
SCHEMBL17790607 SCHEMBL17790607 0.56 1/20
SCHEMBL8504695 SCHEMBL8504695 0.53 1/20
SCHEMBL8770526 SCHEMBL8770526 0.53 1/20
SCHEMBL8910482 SCHEMBL8910482 0.53 1/20
SCHEMBL14416968 SCHEMBL14416968 0.52 1/20
SCHEMBL14416971 SCHEMBL14416971 0.52 1/20
SCHEMBL14525637 SCHEMBL14525637 0.52 1/20
SCHEMBL11440627 SCHEMBL11440627 0.51 1/20
SCHEMBL11440630 SCHEMBL11440630 0.51 1/20
SCHEMBL4670021 SCHEMBL4670021 0.50 1/20
SCHEMBL4670022 SCHEMBL4670022 0.50 1/20

Clinical trials — most relevant to EIF4A2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes PHASE4UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer PHASE1/PHASE2COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients PHASE1/PHASE2COMPLETED
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery PHASE2COMPLETED
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders. PHASE1/PHASE2RECRUITING
Reverse Transcriptase Inhibitors in AGS PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment PHASE1COMPLETED
Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors PHASE1ACTIVE_NOT_RECRUITING
Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus EARLY_PHASE1COMPLETED
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
MEHMO Natural History and Biomarkers nanRECRUITING
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory nanCOMPLETED
Generating Intervals of Reference FFor Early Life Brain Biomarkers. nanRECRUITING
miR-155 Expression in Episodic and Chronic Migraine nanUNKNOWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
The PAH Platform for Deep Phenotyping in Korean Subjects nanUNKNOWN
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress nanWITHDRAWN
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes nanUNKNOWN
miRNA as a Growth Plate Marker After GH nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a EIF4A2 binder may also engage these)

ProteinNameSimilarity
Q5R4X1 1.000 Q5R4X1 →
P10630 1.000 P10630 →
Q3SZ65 1.000 Q3SZ65 →
Q5RKI1 1.000 Q5RKI1 →
Q4R4Y9 1.000 Q4R4Y9 →
Q5ZM36 1.000 Q5ZM36 →
Q9VHS8 1.000 Q9VHS8 →
A6M931 1.000 A6M931 →
EIF4A1 Eukaryotic initiation factor 4A-I 1.000 landscape →
P60843 1.000 P60843 →
Q3B8Q2 1.000 Q3B8Q2 →
Q4R8K5 1.000 Q4R8K5 →
Q8JFP1 1.000 Q8JFP1 →
Q3SZ54 1.000 Q3SZ54 →
Q5R5F5 1.000 Q5R5F5 →
A5A6N4 1.000 A5A6N4 →
Q91VC3 1.000 Q91VC3 →
EIF4A3 Eukaryotic initiation factor 4A-III 1.000 landscape →
Q5VNM3 1.000 Q5VNM3 →
P0CQ70 1.000 P0CQ70 →
Q2NL22 1.000 Q2NL22 →
Q4P184 1.000 Q4P184 →
P10081 1.000 P10081 →
B5DG42 1.000 B5DG42 →
Q4R3Q1 1.000 Q4R3Q1 →
P29562 1.000 P29562 →
B7ZTW1 1.000 B7ZTW1 →
Q40468 1.000 Q40468 →
Q41741 0.999 Q41741 →
Q02748 0.999 Q02748 →